For example, the proliferation marker Ki-67 is used in meningiomas to differentiate cancer into meningothelial (WHO I), atypical (WHO II), and anaplastic (WHO III) and correlates with tumor recurrences [1–5]. This evidence concerns the gene MKI67 and neoplasm.